CG
PCRX icon

Clinton Group’s Pacira BioSciences PCRX Stock Holding History

Clinton Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-4,528
Closed -$348K – 975
2015
Q4 		$348K Buy
+4,528
New +$256K 0.03% 602
2015
Q3 		– Sell
-6,197
Closed -$438K – 808
2015
Q2 		$438K Sell
6,197
-2,410
-28% -$190K 0.06% 399
2015
Q1 		$765K Buy
8,607
+2,155
+33% +$219K 0.2% 149
2014
Q4 		$572K Buy
+6,452
New +$610K 0.18% 207

Other funds holding PCRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Clinton Group's PCRX Position: Q1 2016 in Review

Clinton Group sold out of Pacira BioSciences (PCRX) in Q1 2016, closing a stake of 4,528 shares — an estimated $348K sold.

Clinton Group first reported a position in PCRX in Q4 2014 and held it in 4 quarters. The position peaked at $765K in Q1 2015. 180 funds tracked by Wall St. Rank hold PCRX as of Q1 2016.

  • Clinton Group reported no remaining Pacira BioSciences position as of Q1 2016 after selling out during the quarter.
  • Clinton Group sold 4,528 Pacira BioSciences shares in Q1 2016, an estimated $348K.
  • Clinton Group first reported a position in Pacira BioSciences in Q4 2014 and held it in 4 quarters.
  • Clinton Group's Pacira BioSciences position peaked at $765K in Q1 2015.
  • 180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2016.

Based on Clinton Group's 13F filing for Q1 2016, filed 13 May 2016.